ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 6% planned / 94% discretionary
Largest single sale: $20.8M.
Where they traded
Last open-market purchase: September 18, 2025 — 1.0 years ago, by Gline Matthew .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Fitzgerald Meghan 2 fills | Director | Sell 10b5-1 | 5,112 | $39.74 | $203.2K | 36,508 −12.3% of holding | |
| Epperly Melissa B, 2 fills | Director | Sell 10b5-1 | 4,938 | $39.74 | $196.2K | 10,500 −32% of holding | |
| Fitzgerald Meghan | Director | Sell 10b5-1 | 20,000 | $39.90 | $798.0K | 42,963 −31.8% of holding | |
| Venker Eric 2 fills | President & Immunovant CEO | Sell 10b5-1 | 200,000 | $35.77 | $7.2M | 1,632,972 −10.9% of holding | |
| Sukhatme Mayukh | President & CIO | Sell | 144,756 | $36.48 | $5.3M | 18,630,739 −0.8% of holding | |
| Sukhatme Mayukh | President & CIO | Sell | 17,519 | $37.30 | $653.5K | 18,630,739 −0.1% of holding | |
| Sukhatme Mayukh | President & CIO | Sell | 172,899 | $37.17 | $6.4M | 18,630,739 −0.9% of holding | |
| Sukhatme Mayukh 2 fills | President & CIO | Sell | 136,942 | $36.73 | $5.0M | 18,630,739 −0.7% of holding | |
| Sukhatme Mayukh | President & CIO | Sell | 284,707 | $36.25 | $10.3M | 18,630,739 −1.5% of holding | |
| Sukhatme Mayukh | President & CIO | Sell | 243,177 | $36.23 | $8.8M | 18,630,739 −1.3% of holding | |
| Venker Eric | President & Immunovant CEO | Sell | 200,000 | $34.95 | $7.0M | 1,613,063 −11% of holding | |
| MANCHESTER KEITH S 2 fills | Director | Sell | 212,380 | $35.44 | $7.5M | 13,689,166 −1.5% of holding | |
| QVT Financial LP | Other | Sell | 12,380 | $35.28 | $436.8K | 13,689,166 −0.1% of holding | |
| Gold Daniel Allen | Director | Sell | 12,380 | $35.28 | $436.8K | 13,689,166 −0.1% of holding | |
| Fitzgerald Meghan | Director | Sell | 10,000 | $34.90 | $349.0K | 42,963 −18.9% of holding | |
| MANCHESTER KEITH S 2 fills | Director | Sell | 800,000 | $34.55 | $27.6M | 14,301,546 −5.3% of holding | |
| QVT Financial LP 2 fills | Other | Sell | 800,000 | $34.55 | $27.6M | 14,301,546 −5.3% of holding | |
| Gold Daniel Allen 2 fills | Director | Sell | 800,000 | $34.55 | $27.6M | 14,301,546 −5.3% of holding | |
| Epperly Melissa B, 2 fills | Director | Sell | 17,750 | $34.38 | $610.3K | 19,222 −48% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.